Key Results

CAPRISA 004: topical 1% tenofovir gel applied vaginally within 12 hours before and after sex reduces women's risk by 38%

VOICE: the data review committee recommended that the 1% tenofovir gel arm of the study be stopped because it was safe but not effective

• MTN Statement
• Questions and Answers document on DSMB decision (from MTN)
  
• AVAC Statement
• Listen to a recording of a global teleconference to discuss this development

Trials

This section provides information on ongoing microbicide trials and trial results to date.

The term microbicide refers to various strategies being tested that may reduce the risk of HIV transmission during sex. These include creams, gels, and suppositories that could be used vaginally or rectally. 

• Ongoing Trials: This link will display a PDF document containing the microbicide trials table and product-specific pages that include in-depth information on trials and/or products that AVAC has followed particularly closely.
  

• Trial Results: This section includes information on the results of the trials, both as AVAC covered the releases in real-time and journal articles that include additional data analyses.

• Planned Trials: Information on future microbicide trials is available here.